We @RedefiningMECFS and @AvikRoy74969264 are excited to share some early results of our low dose rapamycin project in its pre-print version here. Thanks to all the patients for participating! .

RT @loscharlos: “David Kaufman, an internal medicine & chronic disease specialist, started prescribing low-dose rapamycin for people with M….

Excited for @RedefiningMECFS (Simmaron) to participate in The Southeastern Wisconsin Consortium of Drug Discovery and Development Meeting @UWM today! Innovation is driven by a strong partnership between academia and industry partners with early support from the federal government.

RT @PlzSolveCFS: 🚨 Big news! Simmaron Research wins our latest Solve #MECFS Catalyst Award! We’re proud to provide funding for the Low-Dose….

Expect more updates soon! Our partnership with @agelessrx_ will help us lead to new therapies (and combinations) using FDA-approved agents in placebo controlled trials.

In Feb 2025 we expanded our original trial and are happy to report that enrollment is soaring, thanks in large part to a partnership with @agelessrx_ who is providing clinical services, centralizing the drug supply and other critical elements.

This trial is not placebo controlled and we understand the limitations; however, our goal was to try and develop a predictive diagnostic to help objectively identify potential responders to therapy. This would be helpful in clinical practice and future double blinded placebo.

We were thankful to run into David Kaufman, MD who has been using rapamycin in his patients and together with this new hypothesis we initiated this trial back in Nov. 2023. Our clinical trial team has grown to include 8 clinical sites including @GrachStephanie and @BatemanHorne.

We got NIH funding to further explore the mechanism of mTOR mediated autophagy disruption as it relates to key ME/CFS symptoms like PEM and published this work .

Our goal with this observational trial was to see if low dose rapamycin could change blood markers of autophagy function, specifically pATG13 based on our previous publication which found it to be elevated in patients with ME/CFS

Autophagy can be inhibited when mTOR activity is high. Rapamycin helps induce autophagy function. This is critical for the removal of metabolically inactive proteins and recycling mitochondria.

We found that a significant proportion of the patients who finished the three month trial period of rapamycin (an mTOR inhibitor) showed improvements in both clinical features of the illness (PEM) and saw improvement in blood based markers of autophagy function.

Elevated ATG13 in serum of patients with ME/CFS stimulates oxidative stress response in microglial cells via activation of receptor for advanced glycation end products (RAGE) - PubMed

Inactivation of ATG13 stimulates chronic demyelinating pathologies in muscle-serving nerves and spinal cord - PubMed

RT @GrachStephanie: Had the honor of presenting the initial patient-reported outcomes of the collaborative rapamycin study led by @Redefini….

So psyched to have @GrachStephanie present some early data on @RedefiningMECFS rapamycin study. Without clinicians like Dr Grach, and our other clinical experts me and @AvikRoy74969264 would have no patients to study. Manuscript is forthcoming! #MECFS #longcovid.

RT @RedefiningMECFS: In our #ME mouse model publication, we show that chronic mTOR activation disrupts autophagy function, leading to #PEM….

Excited to see our recent disease relevant model of PEM was highlighted in @IASPpain “Papers of the Week”. @AvikRoy74969264 @RedefiningMECFS #PEM #ME #LongCovid.

Me and @AvikRoy74969264 at @RedefiningMECFS are excited to share our newest perspective article published in Biomolecules on BH4 metabolism in ME/CFS patients as it relates to OI pathogenesis.#ME/CFS, #POTs #LongCovid .